Filter search criteria using below inputs
Click on magnifying glass icon to search
Company | Country | Symbol |
---|
Time | Volume | MRNA |
---|---|---|
09:32 ET | 89092 | 117.585 |
09:34 ET | 21655 | 117.36 |
09:36 ET | 11993 | 117.5 |
09:38 ET | 18476 | 118.205 |
09:39 ET | 5944 | 118.005 |
09:41 ET | 9810 | 118.315 |
09:43 ET | 20769 | 118.46 |
09:45 ET | 13602 | 117.87 |
09:48 ET | 9940 | 117.63 |
09:50 ET | 11605 | 117.59 |
09:52 ET | 7515 | 117.9473 |
09:54 ET | 12273 | 117.36 |
09:56 ET | 3723 | 117.57 |
09:57 ET | 5680 | 118.0306 |
09:59 ET | 14577 | 118.91 |
10:01 ET | 22791 | 118.6 |
10:03 ET | 7579 | 118.05 |
10:06 ET | 9506 | 117.735 |
10:08 ET | 10671 | 117.63 |
10:10 ET | 8329 | 117.485 |
10:12 ET | 13107 | 117.73 |
10:14 ET | 9924 | 118.185 |
10:15 ET | 15543 | 118.155 |
10:17 ET | 18382 | 118.05 |
10:19 ET | 7299 | 118.21 |
10:21 ET | 5347 | 118.22 |
10:24 ET | 2920 | 118.1566 |
10:26 ET | 10648 | 117.825 |
10:28 ET | 10048 | 117.85 |
10:30 ET | 1123 | 117.84 |
10:32 ET | 18173 | 117.5531 |
10:33 ET | 3474 | 117.265 |
10:35 ET | 26132 | 117.36 |
10:37 ET | 5968 | 117.4609 |
10:39 ET | 27829 | 117.84 |
10:42 ET | 6235 | 117.7 |
Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
---|---|---|---|
Moderna Inc | 44.9B | -7.5x | --- |
ICON PLC | 26.3B | 38.7x | +4.68% |
Biogen Inc | 33.3B | 28.2x | -18.14% |
Biontech SE | 18.7B | 158.8x | --- |
Grifols SA | 5.3B | 22.1x | --- |
Alnylam Pharmaceuticals Inc | 31.3B | -91.5x | --- |
Moderna, Inc. is a biotechnology company. The Company is advancing a new class of medicines made of messenger ribonucleic acid (mRNA). It is developing therapeutics and vaccines for infectious diseases, immuno-oncology, rare diseases and autoimmune diseases, independently and with its strategic collaborators. mRNA medicines are designed to direct the body’s cells to produce intracellular, membrane or secreted proteins that have a therapeutic or preventive benefit with the potential to address a spectrum of diseases. Its diverse development pipeline consists of 45 therapeutic and vaccine programs, nine of which are in late-stage development. Its products include COVID-19 vaccines (mRNA-1273/Spikevax, next-generation mRNA-1283), RSV vaccine (mRNA-1345), Seasonal influenza vaccines (mRNA-1010, mRNA-1011, mRNA-1012, mRNA-1020 and mRNA-1030), Combination vaccines (mRNA-1083, mRNA-1230, mRNA-1045 and mRNA-1365), CMV vaccine (mRNA-1647), EBV vaccine (mRNA-1189 and mRNA-1195) and others.
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $44.9B |
---|---|
Revenue (TTM) | $5.2B |
Shares Outstanding | 383.2M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | 1.66 |
EPS | $-15.66 |
Book Value | $36.27 |
P/E Ratio | -7.5x |
Price/Sales (TTM) | 8.7 |
Price/Cash Flow (TTM) | --- |
Operating Margin | -99.73% |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.